Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Krainer

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
British Journal of Cancer|January 25, 2007
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathwayD Pils, A Pinter, J Reibenwein, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell linesS Tomek, W Koestler, P Horak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trialW J Köstler, T Brodowicz, Y Attems, et al.
Cancer Research|August 27, 1999
Common nonsense mutations in RAD52D W Bell, D C Wahrer, D H Kang, et al.
Oral Diseases|August 16, 2012
HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancerC Perisanidis, B Savarese-Brenner, T Würger, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?G J Locker, G G Steger, M F Gnant, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factorH Stöger, H Samonigg, M Krainer, et al.
The New England Journal of Medicine|May 15, 1997
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancerM Krainer, S Silva-Arrieta, M G FitzGerald, et al.
Journal of Clinical Medicine|April 30, 2021
Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B MutationsMichael W Hess, Iris M Krainer, Przemyslaw A Filipek, et al.
JCI Insight|July 21, 2017
Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutationsGeorg F Vogel, Jorik M van Rijn, Iris M Krainer, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|January 25, 2007
In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathwayD Pils, A Pinter, J Reibenwein, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell linesS Tomek, W Koestler, P Horak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trialW J Köstler, T Brodowicz, Y Attems, et al.
Cancer Research|August 27, 1999
Common nonsense mutations in RAD52D W Bell, D C Wahrer, D H Kang, et al.
Oral Diseases|August 16, 2012
HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancerC Perisanidis, B Savarese-Brenner, T Würger, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?G J Locker, G G Steger, M F Gnant, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factorH Stöger, H Samonigg, M Krainer, et al.
The New England Journal of Medicine|May 15, 1997
Differential contributions of BRCA1 and BRCA2 to early-onset breast cancerM Krainer, S Silva-Arrieta, M G FitzGerald, et al.
Journal of Clinical Medicine|April 30, 2021
Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B MutationsMichael W Hess, Iris M Krainer, Przemyslaw A Filipek, et al.
JCI Insight|July 21, 2017
Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutationsGeorg F Vogel, Jorik M van Rijn, Iris M Krainer, et al.
Pageof 5